Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr
Shattuck Labs (STTK) priced its previously announced public offering of 10.88 million shares at $4.00 each, and said it will also issue pre-funded warrants for up to 7.87 million shares at $3.9999 per warrant. The company expects about $75 million in gross proceeds and said the deal should close June 11. Underwriters have a 30-day option for up to 2.81 million additional shares.
Dilutive equity financing at a fixed price is likely to pressure near-term valuation, while providing cash runway.
Shattuck Labs priced a public offering of 10.88M shares at $4.00 and pre-funded warrants, raising ~$75M gross and diluting shares.
Near-term downside/volatility risk around dilution and closing; upside depends on whether proceeds materially extend funding and reduce financing risk.
Background
The company had previously announced the offering; this article reports the final pricing and warrant terms.
Why it matters
The fixed offering price ($4.00) versus the prior close ($4.27) implies immediate dilution pressure, while the ~$75M gross proceeds may reduce near-term financing uncertainty.
Market relevance
A priced equity raise with warrants is a direct, tradable catalyst for dilution/overhang and cash-runway expectations.
Market effects
Adds another clinical-stage biotech example of equity financing, reinforcing dilution risk as a recurring theme in the group.
Primarily impacts US Nasdaq biotech sentiment; limited spillover beyond small-cap biotech complex.
Low—financing is company-specific and not tied to a global macro/regulatory shock.
Alternative perspectives
If the proceeds meaningfully extend cash runway or de-risk upcoming clinical milestones, the market may re-rate the stock despite dilution.
Watch the overhang into closing and any follow-on guidance on use of proceeds; warrant structure can also affect hedging/flow dynamics.
Key entities
- companyShattuck Labs
Clinical-stage biotech that priced a common stock public offering and pre-funded warrants.
- transactionPublic offering
10.88M shares at $4.00 plus pre-funded warrants for up to 7.87M shares; underwriters have a 30-day option for 2.81M more shares.
